ATLANTA--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that Dr. Greg L. Kaluza, M.D., Ph.D, a widely recognized expert in the field of interventional cardiology, has joined the company’s Scientific Advisory Board, where he will help guide the company’s clinical trials and other key research programs.
